Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Badanie mające na celu ocenę skuteczności i bezpieczeństwa/tolerancji podskórnego tyldrakizumabu (SCH 900222/MK-3222) u uczestników z przewlekłą łuszczycą plackowatą o nasileniu umiarkowanym do ciężkiego, po którym przeprowadzono długoterminowe badanie przedłużone (MK-3222-011) (reSURFACE 2)

3 listopada 2026 zaktualizowane przez: Sun Pharmaceutical Industries Limited

52-tygodniowe, fazy 3, randomizowane badanie równoległe z aktywnym lekiem porównawczym i kontrolowanym placebo w celu oceny skuteczności i bezpieczeństwa/tolerancji tyldrakizumabu podawanego podskórnie (SCH 900222/MK-3222), po którym następuje opcjonalne długoterminowe badanie przedłużające bezpieczeństwo u pacjentów z przewlekłą łuszczycą plackowatą o nasileniu umiarkowanym do ciężkiego (protokół nr MK-3222-011)

This study is being conducted to evaluate the efficacy and safety/tolerability of tildrakizumab (SCH 900222/MK-3222) in a population of participants with moderate-to-severe plaque psoriasis. The primary hypotheses of the study are that tildrakizumab is superior to placebo in the treatment of moderate-to-severe chronic plaque psoriasis as measured by the proportion of participants achieving >= Psoriasis Area Sensitivity Index of 75% (PASI-75) response and the proportion of participants with a Physician's Global Assessment (PGA) score of "clear" or "minimal" with at least a 2 grade reduction from baseline at Week 12.

Przegląd badań

Szczegółowy opis

The base study consists of a screening phase of up to 4 weeks followed by a treatment period of 52 weeks, and a 20-week follow-up period. The base study treatment period is divided into 3 sequential parts.

In Part 1 of the base study (Week 0 to Week 12), participants will be randomized to one of 4 study arms (Arm A: tildrakizumab 200 mg + matching placebo to etanercept; Arm B: tildrakizumab 100 mg + matching placebo to etanercept; Arm C: matching placebo to tildrakizumab + matching placebo to etanercept; Arm D: matching placebo to tildrakizumab + etanercept 50 mg).

In Part 2 of the base study (Week 12 to Week 28), participants in Arm A and Arm B will receive matching placebo to tildrakizumab to maintain blinding at Week 12 and will receive either tildrakizumab 200 mg (Arm A) or tildrakizumab 100 mg (Arm B) at Weeks 12 and 16. Participants in Arm A and Arm B will also receive matching placebo to etanercept once weekly through study Week 28. At study Week 12, Arm C participants will be re-randomized to receive their first dose of tildrakizumab 200 mg or tildrakizumab 100 mg, and will receive additional doses of study medication according to their re-randomized treatment assignment at Week 16. Participants in Arm C will also receive matching placebo to etanercept through treatment Week 28. Participants in Arm D will continue with once weekly doses of etanercept through study Week 28 in combination with matching placebo to tildrakizumab.

In Part 3 of the base study (Week 28 to Week 52), participants in Arm A with >= PASI-75 response at Week 28 will be re-randomized to either continue tildrakizumab 200 mg or receive tildrakizumab 100 mg at study Weeks 28, 40, and 52. Participants with >= PASI-50 response but < PASI-75 response will continue to receive tildrakizumab 200 mg every 12 weeks and those participants with < PASI-50 response will be discontinued from the study. Participants in Arm B with >= PASI-75 response at Week 28 will continue to receive tildrakizumab 100 mg every 12 weeks. Those with >= PASI-50 response but < PASI-75 response will be re-randomized to receive continued tildrakizumab 100 mg or tildrakizumab 200 mg every 12 weeks. Participants in Arm B with < PASI-50 response will be discontinued from the study. Participants in Arm C will continue to receive treatment every 12 weeks according to their re-randomized treatment assignment. Participants in Arm D that achieve >= PASI-75 response at Week 28 will be discontinued from the study. Those participants with < PASI-75 response at Week 28 will be crossed over to tildrakizumab 200 mg to receive doses at Weeks 32, 36 and 48.

Eligible participants that choose to enroll in the extension study will have an additional treatment period of up to 192 weeks and will be monitored for an additional 20 weeks in the follow-up period. Each participant will receive tildrakizumab 200 mg or tildrakizumab 100 mg every 12 weeks up to study Week 244 according to their treatment assignment at the conclusion of Part 3 of the base study.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

1090

Faza

  • Faza 3

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Clinical diagnosis of moderate-to-severe plaque psoriasis for at least 6 months prior to enrollment;
  • Candidate for phototherapy or systemic therapy;
  • Premenopausal female participants must agree to abstain from heterosexual activity or use a medically approved method of contraception or use appropriate effective contraception as per local regulations or guidelines
  • For the extension study: must have completed Part 3 of the base study
  • For the extension study: must have achieved at least a PASI-50 response by the end of Part 3 of the base study

Exclusion Criteria:

  • Non-plaque forms of psoriasis
  • Presence or history of severe psoriatic arthritis and is well-controlled on current treatment regimen
  • Women of childbearing potential who are pregnant, intend to become pregnant, or are lactating
  • Participant is expected to require topical therapy, phototherapy, or systemic therapy during the trial
  • Presence of any infection or history of recurrent infection requiring treatment with systemic antibiotics
  • Previous use of entanercept, tildrakizumab (MK-3222), or other interleukin-23 (IL-23)/T- helper cell 17 (Th-17) pathway inhibitors including p40, p19, and IL-17 antagonists
  • Latex allergy or sensitivity
  • Active or untreated latent tuberculosis (TB)
  • For the extension study: women of child-bearing potential who are pregnant, intend to become pregnant within 6 months of completing the trial, or are breast feeding
  • For the extension study: active or uncontrolled significant organ dysfunction or clinically significant laboratory abnormalities
  • For the extension study: expected to require topical treatment, phototherapy, or systemic treatment during the extension study

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Poczwórny

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Tildrakizumab 200 mg

Participants receive tildrakizumab 200 mg subcutaneously (SC) on Weeks 0, 4, 16, 28, 40 and 52 and, optionally, every 12 weeks thereafter until Week 244, plus etanercept placebo (PBO) twice weekly until Week 12 and once weekly from Week 12 to Week 28.

Tildrakizumab 200 mg administered SC. Each pre-filled syringe (PFS) or autoinjector (AI) contains 1 mL of solution, tildrakizumab 100 mg/mL.

Inne nazwy:
  • SCH 900222, MK-3222

Matching placebo to etanercept administered SC

Eksperymentalny: Tildrakizumab 100 mg

Participants receive tildrakizumab 100 mg SC on Weeks 0, 4, 16, 28, 40 and 52 and, optionally, every 12 weeks thereafter until Week 244, plus etanercept placebo twice weekly until Week 12 and once weekly from Week 12 to Week 28.

Matching placebo to etanercept administered SC

Tildrakizumab 100 mg administered SC. Each PFS or AI contains 1 mL of solution, tildrakizumab 100 mg/mL.

Inne nazwy:
  • SCH 900222, MK-3222
Komparator placebo: Placebo

Participants receive matching placebo to tildrakizumab SC on Weeks 0 and 4 plus etanercept placebo twice weekly up to Week 12 and once weekly from Week 12 to Week 28. Participants will be re-randomized 1:1 at Week 12 to receive tildrakizumab 200 mg or tildrakizumab 100 mg on Weeks 12, 16, 28, 40 and 52 and, optionally, every 12 weeks thereafter until Week 244.

Matching placebo to etanercept administered SC

Matching placebo to tildrakizumab administered SC

Aktywny komparator: Etanercept 50 mg

Participants receive matching placebo to tildrakizumab SC on Weeks 0 and 4 and etanercept 50 mg twice weekly up to Week 12 and once weekly from Week 12 to Week 28. Participants who don't achieve PASI-75, receive tildrakizumab 200 mg after Week 28 (Weeks 32, 36 and 48) and, optionally, every 12 weeks thereafter until Week 244.

Matching placebo to tildrakizumab administered SC

Etanercept 50 mg administered SC

Inne nazwy:
  • Embrel

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Percentage of Participants Achieving a Psoriasis Area Sensitivity Index 75% (PASI-75) Response at Week 12 (Part 1)
Ramy czasowe: Week 12

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-75 response indicates the number of participants achieving a 75% reduction in PASI score compared to baseline. Statistical analyses presented below compare tildrakizumab to placebo to support the primary hypothesis of the study.

Week 12
Percentage of Participants With a Physician's Global Assessment (PGA) Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 12 (Part 1)
Ramy czasowe: Week 12

The PGA is used to determine the overall severity of a participant's psoriasis lesions at a given time point. Overall lesions will be graded for thickness, erythema, and scaling on a scale from 0 to 5. The sum of the 3 scales will be divided by 3 to obtain the PGA score. PGA is assessed as: 0= Cleared, except for residual discoloration. 1= Minimal, majority of lesions have individual scores that average 1. 2 =Mild, majority of lesions have individual scores that average 2. 3= Moderate, majority of lesions have individual scores that average 3. 4= Marked, majority of lesions have individual scores that average 4. 5= Severe, majority of lesions have individual scores that average 5. Statistical analyses presented below compare tildrakizumab to placebo to support the primary hypothesis of the study.

Week 12
Percentage of Participants Experiencing an Adverse Event (AE) Up to Week 12 (Part 1)
Ramy czasowe: Up to Week 12

An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

Up to Week 12
Percentage of Participants Discontinuing Study Treatment Due to an AE Up to Week 12 (Part 1)
Ramy czasowe: Up to Week 12

An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

Up to Week 12

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Percentage of Participants Achieving a PASI-75 Response at Week 28 (Part 2)
Ramy czasowe: Week 28

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-75 response indicates the number of participants achieving a 75% reduction in PASI score compared to baseline. Primary analysis for this endpoint is for participants randomized to tildrakizumab 200 mg, tildrakizumab 100 mg, or etanercept in Part 1.

Week 28
Percentage of Participants Achieving a PASI-75 Response at Week 40 (Part 3)
Ramy czasowe: Week 40

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-75 response indicates the number of participants achieving a 75% reduction in PASI score compared to baseline. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and <75% improvement in PASI response from baseline at Week 28.

Week 40
Percentage of Participants Achieving a PASI-75 Response at Week 52 (Part 3)
Ramy czasowe: Week 52

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-75 response indicates the number of participants achieving a 75% reduction in PASI score compared to baseline. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and <75% improvement in PASI response from baseline at Week 28.

Week 52
Percentage of Participants With a PGA Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 28 (Part 2)
Ramy czasowe: Week 28

The PGA is used to determine the overall severity of a participant's psoriasis lesions at a given time point. Overall lesions will be graded for thickness, erythema, and scaling on a scale from 0 to 5. The sum of the 3 scales will be divided by 3 to obtain the PGA score. PGA is assessed as: 0= Cleared, except for residual discoloration. 1= Minimal, majority of lesions have individual scores that average 1. 2 =Mild, majority of lesions have individual scores that average 2. 3= Moderate, majority of lesions have individual scores that average 3. 4= Marked, majority of lesions have individual scores that average 4. 5= Severe, majority of lesions have individual scores that average 5.

Week 28
Percentage of Participants With a PGA Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 40 (Part 3)
Ramy czasowe: Week 40

The PGA is used to determine the overall severity of a participant's psoriasis lesions at a given time point. Overall lesions will be graded for thickness, erythema, and scaling on a scale from 0 to 5. The sum of the 3 scales will be divided by 3 to obtain the PGA score. PGA is assessed as: 0= Cleared, except for residual discoloration. 1= Minimal, majority of lesions have individual scores that average 1. 2 =Mild, majority of lesions have individual scores that average 2. 3= Moderate, majority of lesions have individual scores that average 3. 4= Marked, majority of lesions have individual scores that average 4. 5= Severe, majority of lesions have individual scores that average 5. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and <75% improvement in PASI response from baseline at Week 28.

Week 40
Percentage of Participants With a PGA Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 52 (Part 3)
Ramy czasowe: Week 52

The PGA is used to determine the overall severity of a participant's psoriasis lesions at a given time point. Overall lesions will be graded for thickness, erythema, and scaling on a scale from 0 to 5. The sum of the 3 scales will be divided by 3 to obtain the PGA score. PGA is assessed as: 0= Cleared, except for residual discoloration. 1= Minimal, majority of lesions have individual scores that average 1. 2 =Mild, majority of lesions have individual scores that average 2. 3= Moderate, majority of lesions have individual scores that average 3. 4= Marked, majority of lesions have individual scores that average 4. 5= Severe, majority of lesions have individual scores that average 5. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and <75% improvement in PASI response from baseline at Week 28.

Week 52
Percentage of Participants Achieving a PASI-90 Response at Week 12 (Part 1)
Ramy czasowe: Week 12

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-90 response indicates the number of participants achieving a 90% reduction in PASI score compared to baseline.

Week 12
Percentage of Participants Achieving a PASI-90 Response at Week 28 (Part 2)
Ramy czasowe: Week 28

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-90 response indicates the number of participants achieving a 90% reduction in PASI score compared to baseline.

Week 28
Percentage of Participants Achieving a PASI-90 Response at Week 40 (Part 3)
Ramy czasowe: Week 40

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-90 response indicates the number of participants achieving a 90% reduction in PASI score compared to baseline. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and <75% improvement in PASI response from baseline at Week 28.

Week 40
Percentage of Participants Achieving a PASI-90 Response at Week 52 (Part 3)
Ramy czasowe: Week 52

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-90 response indicates the number of participants achieving a 90% reduction in PASI score compared to baseline. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and <75% improvement in PASI response from baseline at Week 28.

Week 52
Percentage of Participants Achieving a PASI-100 Response at Week 12 (Part 1)
Ramy czasowe: Week 12

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-100 response indicates the number of participants achieving a 100% reduction in PASI score compared to baseline.

Week 12
Percentage of Participants Achieving a PASI-100 Response at Week 28 (Part 2)
Ramy czasowe: Week 28

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-100 response indicates the number of participants achieving a 100% reduction in PASI score compared to baseline.

Week 28
Percentage of Participants Achieving a PASI-100 Response at Week 40 (Part 3)
Ramy czasowe: Week 40

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-100 response indicates the number of participants achieving a 100% reduction in PASI score compared to baseline. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and <75% improvement in PASI response from baseline at Week 28.

Week 40
Percentage of Participants Achieving a PASI-100 Response at Week 52 (Part 3)
Ramy czasowe: Week 52

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-100 response indicates the number of participants achieving a 90% reduction in PASI score compared to baseline. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and <75% improvement in PASI response from baseline at Week 28.

Week 52
Baseline Dermatology Life Quality Index (DLQI)
Ramy czasowe: Baseline

The DLQI questionnaire consists of 10 questions, where each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score is the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life.

Baseline
Change From Baseline in the DLQI at Week 12 (Part 1)
Ramy czasowe: Baseline and Week 12

The DLQI questionnaire consists of 10 questions, where each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score is the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life.

Baseline and Week 12
Change From Baseline in the DLQI at Week 28 (Part 2)
Ramy czasowe: Baseline and Week 28

The DLQI questionnaire consists of 10 questions, where each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score is the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life.

Baseline and Week 28
Change From Baseline in the DLQI at Week 40 (Part 3)
Ramy czasowe: Baseline and Week 40

The DLQI questionnaire consists of 10 questions, where each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score is the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and <75% improvement in PASI response from baseline at Week 28.

Baseline and Week 40
Change From Baseline in the DLQI at Week 52 (Part 3)
Ramy czasowe: Baseline and Week 52

The DLQI questionnaire consists of 10 questions, where each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score is the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and <75% improvement in PASI response from baseline at Week 28.

Baseline and Week 52
Percentage of Participants With a DLQI Score of 0 or 1 at Week 12 (Part 1)
Ramy czasowe: Week 12

The DLQI questionnaire consists of 10 questions, where each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score is the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life.

Week 12
Percentage of Participants With a DLQI Score of 0 or 1 at Week 28 (Part 2)
Ramy czasowe: Week 28

The DLQI questionnaire consists of 10 questions, where each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score is the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life.

Week 28
Percentage of Participants With a DLQI Score of 0 or 1 at Week 40 (Part 3)
Ramy czasowe: Week 40

The DLQI questionnaire consists of 10 questions, where each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score is the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and <75% improvement in PASI response from baseline at Week 28.

Week 40
Percentage of Participants With a DLQI Score of 0 or 1 at Week 52 (Part 3)
Ramy czasowe: Week 52

The DLQI questionnaire consists of 10 questions, where each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score is the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and <75% improvement in PASI response from baseline at Week 28.

Week 52
Mean Change From Baseline in PASI Score Over Time (Part 1)
Ramy czasowe: Baseline and Week 4, Week 8 or Week 12

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status.

Baseline and Week 4, Week 8 or Week 12
Mean Change From Baseline in PASI Score Over Time (Part 2)
Ramy czasowe: Baseline and Week 16, Week 22 or Week 28

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status.

Baseline and Week 16, Week 22 or Week 28
Mean Change From Baseline in PASI Score Over Time (Part 3)
Ramy czasowe: Baseline and Week 32, Week 36, Week 40, Week 46 and Week 52

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and <75% improvement in PASI response from baseline at Week 28.

Baseline and Week 32, Week 36, Week 40, Week 46 and Week 52
Mean Percent Change From Baseline in PASI Score Over Time (Part 1)
Ramy czasowe: Baseline and Week 4, Week 8 or Week 12

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status.

Baseline and Week 4, Week 8 or Week 12
Mean Percent Change From Baseline in PASI Score Over Time (Part 2)
Ramy czasowe: Baseline and Week 16, Week 22 or Week 28

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status.

Baseline and Week 16, Week 22 or Week 28
Mean Percent Change From Baseline in PASI Score Over Time (Part 3)
Ramy czasowe: Baseline and Week 32, Week 36, Week 40, Week 46 and Week 52

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. Week-28 responder (Wk-28 R) is a participant who achieved ≥ 75% improvement in PASI from baseline at Week 28. Week-28 partial responder (Wk-28 PR) is a participant who achieved ≥50% and <75% improvement in PASI response from baseline at Week 28.

Baseline and Week 32, Week 36, Week 40, Week 46 and Week 52
Proportion of Subjects With PASI 50 Response Over Time Among PASI 50 Responders at Week 52 (Extension Study)
Ramy czasowe: Week 60, 112, 172, 220, 268, 316, 364 and 396.

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the amount of body surface for each region involved (head=0.1; upper limbs=0.2; trunk= 0.3; and lower limbs=0.4) and the degree of involvement for each body region (0=no involvement to 6=90-100% involvement). Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-50 response indicates the number of participants achieving a 50% reduction in PASI score compared to baseline.

Week 60, 112, 172, 220, 268, 316, 364 and 396.
Proportion of Subjects With PASI 75 Response Over Time Among PASI 75 Responders at Week 52 (Extension Study)
Ramy czasowe: Week 60, 112, 172, 220, 268, 316, 364 and 396.

The Psoriasis Area Severity Index is a measure of the average redness, thickness, and scaliness of the lesions (each graded on a 0-4 scale), weighed by the area of involvement. Such calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status.

PASI 75, PASI 90, PASI 100 stand for the status (Yes/No) of achieving ≥ 75%,≥90%, ≥100% reduction from baseline in PASI (Psoriasis Area-and-Severity Index) score, respectively.

Week 60, 112, 172, 220, 268, 316, 364 and 396.
Proportion of Subjects With PASI 90 Response Over Time Among PASI 90 Responders at Week 52 (Extension Study)
Ramy czasowe: Week 60, 112, 172, 220, 268, 316, 364 and 396.

The Psoriasis Area Severity Index is a measure of the average redness, thickness, and scaliness of the lesions (each graded on a 0-4 scale), weighed by the area of involvement. Such calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status.

PASI 75, PASI 90, PASI 100 stand for the status (Yes/No) of achieving ≥ 75%,≥90%, ≥100% reduction from baseline in PASI (Psoriasis Area-and-Severity Index) score, respectively.

Week 60, 112, 172, 220, 268, 316, 364 and 396.
Proportion of Subjects With PASI 100 Response Over Time Among PASI 100 Responders at Week 52 (Extension Study)
Ramy czasowe: Week 60, 112, 172, 220, 268, 316, 364

The Psoriasis Area Severity Index is a measure of the average redness, thickness, and scaliness of the lesions (each graded on a 0-4 scale), weighed by the area of involvement. Such calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status.

PASI 75, PASI 90, PASI 100 stand for the status (Yes/No) of achieving ≥ 75%,≥90%, ≥100% reduction from baseline in PASI (Psoriasis Area-and-Severity Index) score, respectively.

Week 60, 112, 172, 220, 268, 316, 364
Change From Baseline in Psoriasis Area and Severity Index Score Over Time (Extension Study)
Ramy czasowe: Week 60, 112, 172, 220, 268, 316, 364

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status.

Week 60, 112, 172, 220, 268, 316, 364
Percent Change From Baseline in Psoriasis Area and Severity Index Score Over Time (Extension Study)
Ramy czasowe: Week 60, 112, 172, 220, 268, 316, 364

The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the area of involvement. Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status.

Week 60, 112, 172, 220, 268, 316, 364
Percentage of Participants With a PGA Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline (Extension Study)
Ramy czasowe: Week 60, 112, 172, 220, 268, 316, 364

The PGA is used to determine the overall severity of a participant's psoriasis lesions at a given time point. Overall lesions will be graded for thickness, erythema, and scaling on a scale from 0 to 5. The sum of the 3 scales will be divided by 3 to obtain the PGA score.

PGA is assessed as: 0= Cleared, except for residual discoloration.

1= Minimal, majority of lesions have individual scores that average 1. 2 =Mild, majority of lesions have individual scores that average 2. 3= Moderate, majority of lesions have individual scores that average 3. 4= Marked, majority of lesions have individual scores that average 4. 5= Severe, majority of lesions have individual scores that average 5.

Week 60, 112, 172, 220, 268, 316, 364
Percentage of Subjects With a PASI75 Response Over Time (Extension Study)
Ramy czasowe: Week 60, 112, 172, 220, 268, 316, 364

The Psoriasis Area Severity Index is a measure of the average redness, thickness, and scaliness of the lesions (each graded on a 0-4 scale), weighed by the area of involvement. Such calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status.

PASI 75, PASI 90, PASI 100 stand for the status (Yes/No) of achieving ≥ 75%,≥90%, ≥100% reduction from baseline in PASI (Psoriasis Area-and-Severity Index) score, respectively.

Week 60, 112, 172, 220, 268, 316, 364
Percentage of Subjects With a PASI90 Response Over Time (Extension Study)
Ramy czasowe: Week 60, 112, 172, 220, 268, 316, 364

The Psoriasis Area Severity Index is a measure of the average redness, thickness, and scaliness of the lesions (each graded on a 0-4 scale), weighed by the area of involvement. Such calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status.

PASI 75, PASI 90, PASI 100 stand for the status (Yes/No) of achieving ≥ 75%,≥90%, ≥100% reduction from baseline in PASI (Psoriasis Area-and-Severity Index) score, respectively.

Week 60, 112, 172, 220, 268, 316, 364
Percentage of Subjects With a PASI100 Response Over Time (Extension Study)
Ramy czasowe: Week 60, 112, 172, 220, 268, 316, 364

The Psoriasis Area Severity Index is a measure of the average redness, thickness, and scaliness of the lesions (each graded on a 0-4 scale), weighed by the area of involvement. Such calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status.

PASI 75, PASI 90, PASI 100 stand for the status (Yes/No) of achieving ≥ 75%,≥90%, ≥100% reduction from baseline in PASI (Psoriasis Area-and-Severity Index) score, respectively.

Week 60, 112, 172, 220, 268, 316, 364

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Publikacje ogólne

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

5 lutego 2013

Zakończenie podstawowe (Rzeczywisty)

28 września 2015

Ukończenie studiów (Rzeczywisty)

26 października 2021

Daty rejestracji na studia

Pierwszy przesłany

13 listopada 2012

Pierwszy przesłany, który spełnia kryteria kontroli jakości

14 listopada 2012

Pierwszy wysłany (Szacowany)

20 listopada 2012

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

5 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

3 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj